CLSN - Celsion Corporation

NasdaqCM - NasdaqCM Delayed price. Currency in USD
2.67
+0.03 (+1.14%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close2.64
Open2.60
Bid2.60 x 400
Ask3.80 x 300
Day's range2.59 - 2.69
52-week range0.19 - 6.06
Volume179,102
Avg. volume1,807,662
Market cap42.886M
Beta1.80
PE ratio (TTM)N/A
EPS (TTM)-4.89
Earnings date18 May 2017 - 19 May 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.00
Trade prices are not sourced from all markets
  • Globe Newswire2 days ago

    Celsion Corporation Provides Corporate Update and 2018 Outlook

    Company Advances ThermoDox® for Treatment of Primary Liver Cancer Following Independent Data Monitoring Committee’s Unanimous Recommendation to Continue Phase III OPTIMA Study OPTIMA Study Enrollment Reached 74% Enrollment at Year-End, With Enrollment Completion Expected in Third Quarter 2018 Initiation of Enrollment of Phase I Portion of OVATION II Study of GEN-1 for Treatment of Ovarian Cancer Anticipated in the First Half of 2018 Cash Position of $25.5 Million at Year-End 2017 Provides Runway to Advance Development Priorities into Third Quarter of 2019

  • Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod
    Zacks15 days ago

    Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod

    Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.

  • Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
    Zacks16 days ago

    Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling

    Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling

  • MarketWatch16 days ago

    Celsion shares rise 20% after FDA clears its ovarian cancer therapy for a phase 1/2 trial

    Celsion Corp. shares rose nearly 20% in premarket trade Thursday after the company said the Food and Drug Administration had cleared its ovarian cancer therapy for a phase 1/2 clinical trial. The company ...

  • Globe Newswire16 days ago

    Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer

    LAWRENCEVILLE, N.J., Jan. 04, 2018 (GLOBE NEWSWIRE) --  Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the U.S. Food and Drug Administration (FDA), following the customary 30 day review period, has accepted its submission without comment, providing clearance for the OVATION II Study, the Company’s planned Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer.  The Phase I/II trial was developed with extensive input from the Company’s Medical Advisory Board. The OVATION II Study builds on the highly promising clinical and translational research data from the Phase IB dose-escalating OVATION Study where enrolled patients received escalating weekly doses of GEN-1, from levels beginning at 36mg/m², to 47mg/m², 61mg/m² and 79mg/m² weekly for 8 treatments in total, in combination with neoadjuvant chemotherapy, followed by interval debulking surgery.

  • 5 Breakout Stocks Offering Terrific Returns
    Zacks17 days ago

    5 Breakout Stocks Offering Terrific Returns

    If properly implemented, such a strategy could deliver impressive returns.

  • Cancer Space Last Week Update: Pipeline Expansion in Focus
    Zacks3 months ago

    Cancer Space Last Week Update: Pipeline Expansion in Focus

    Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

  • Celsion's Immunotherapy Candidate Impresses, Stock Surges
    Zacks4 months ago

    Celsion's Immunotherapy Candidate Impresses, Stock Surges

    Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes